Q-omics provides the consensus-scored NT5M profile across patient tissues and cancer cell-line models. NT5M expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NT5M is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, NT5M RNA expression shows 17,984 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRP as cancer lineages where NT5M shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NT5M — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NT5M survival associations across molecular data types. NT5M RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NT5M RNA expression–survival associations across cancer types. High NT5M expression shows unfavorable associations in ACC, UVM, BLCA and KICH, but favorable associations in OV and PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NT5M RNA expression.
This table summarizes NT5M tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for NT5M. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NT5M shows higher tumor expression in KIRP, LIHC, LUAD, LUSC, BRCA and CHOL. The KIRP box plot shows higher NT5M RNA expression in tumor versus normal tissue (log2 FC = +1.076, t-test p < 0.001).
This table shows molecular features associated with NT5M in patient tissues and cancer cell lines. In patient samples, NT5M shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NT5M RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in CNS and BONE.
